Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Solomon BJ, et al. Among authors: hayashi h. J Clin Oncol. 2022 Nov 1;40(31):3593-3602. doi: 10.1200/JCO.21.02278. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605188 Free PMC article. Clinical Trial.
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K. Tanizaki J, et al. Among authors: hayashi h. Clin Cancer Res. 2012 Nov 15;18(22):6219-26. doi: 10.1158/1078-0432.CCR-12-0392. Epub 2012 Jul 27. Clin Cancer Res. 2012. PMID: 22843788
Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K. Kogita A, et al. Among authors: hayashi h. Int J Oncol. 2014 Oct;45(4):1430-6. doi: 10.3892/ijo.2014.2574. Epub 2014 Aug 1. Int J Oncol. 2014. PMID: 25096400 Free PMC article.
MEK inhibitors against MET-amplified non-small cell lung cancer.
Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Chiba M, et al. Among authors: hayashi h. Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17. Int J Oncol. 2016. PMID: 27748834 Free PMC article.
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K. Hayashi H, et al. J Clin Oncol. 2019 Mar 1;37(7):570-579. doi: 10.1200/JCO.18.00771. Epub 2019 Jan 17. J Clin Oncol. 2019. PMID: 30653423 Clinical Trial.
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K, Atagi S, Iwamoto Y, Hayashi H, Okamoto I, Saka H, Mitsuoka S, Fujimoto D, Nishino K, Horiike A, Daga H, Sone T, Yamamoto N, Nakagawa K, Nakanishi Y. Seto T, et al. Among authors: hayashi h. J Clin Oncol. 2020 Mar 10;38(8):793-803. doi: 10.1200/JCO.19.01494. Epub 2019 Dec 27. J Clin Oncol. 2020. PMID: 31880966 Clinical Trial.
6,421 results